COMPARISON OF EFFECTS OF ENALAPRIL AND UNCONTROLLED ANTIHYPERTENSIVE THERAPY ON INSULIN RESISTANCE, ENDOTHELIUM FUNCTION, MARKERS OF INFLAMMATION AND PLATELET ACTIVITY IN PATIENTS WITH METABOLIC SYNDROME

Aim. To assess influence of enalapril and uncontrolled antihypertensive therapy on insulin resistance, endothelium function, markers of inflammation, and platelet activity in patients with metabolic syndrome (MS). Material and methods. 41 patients with MS (21 women and 20 men, aged 58±2 years) were included into open parallel controlled study. MS was defined according to III report of USA Educational Program on cholesterol (2001). Patients were divided into 2 groups. Patients of the 1st group received enalapril (Enam, Dr. Reddy’s) 10 mg daily with further dose titration to 20 mg daily. Patients of the  2nd group continued receiving the same antihypertensive therapy as before (15% - inhibitors of angiotensin converting enzymes, 15% - в-blockers, 15% - diuretics, and 20% of patients - combined therapy). Study duration was 12 weeks. Results. Therapy with enalapril during 3 months resulted into significant decrease in systolic and diastolic blood pressure (BP) by 13 and 9% respectively. BP level decreased insignificantly (by 4,5 and 2% respectively) in controlled group. Ratio of plasma concentration of glucose to insulin in the 1st group increased by 14% before glucose load, and by 25% (p<0,05) 2 hours after peroral glucose load, while in the 2nd group decrease in these figures was noted by 12 and 5% respectively. This shows that treatment with enalapril, unlike uncontrolled antihypertensive therapy, lead to decrease in insulin resistance. Cuff test revealed significant increase in growth of brachial artery diameter in the group of patients, who received enalapril (12% before treatment, and 17% after treatment). Regular antihypertensive therapy didn’t change this parameter significantly (13 and 13,8% respectively). C-reactive protein level decreased by 48% (p<0,05) in the 1st group. Insignificant increase of this marker’s level was observed in the 2nd group. Platelet functional activity in both groups didn’t change significantly. Conclusion.  Together with strong antihypertensive effect, enalapril monotherapy is more efficient than regular antihypertensive therapy in reducing insulin resistance and chronic subclinical inflammation, as well as it has priority in improving endothelium depending vasodilatation.

1. Vogel R.A. Coronary risk factors, endothdial function and atherosclerosis. A review. Clin Cardiol 1997;20:5:428-432.

2. Reaven G.M. Insulin resistancefcoinpensaiory hyperinsulinernia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;38:6:2399-2403.

3. Небиеридзе Д.В., Оганов Р.Г Метаболические и сосудистые эффекты антигипертензивной терапии. М: "Универсум Паблишинг" 2005;32-38.

4. Манухина Е.Б., Малышев И.Ю., Бульвальцев В.И. Эндотелиальная дисфункция и артериальная гипертензия: механизмы и пути коррекции. Кардиоваскулярняя терапия и профилактика 2003;2:4:26-31.

5. Britten М., Schuchinger V. The role ot endothelial function for ischemic manifestation of coronary atherosclerosis. Herz 1998;23:2:97-105.

6. Чазова И.М., Мынка В.Б., Беленков Ю.Н. Эффективность квинаприла у больных с множественными факторами сердечно- сосудистого риска. Кардиоваскулярная терапия и профилактика 2004;3:6:45-52.

7. Expert Panel on Detection. Evaluation and Trestment of High Blood Cholesterol in Adufts. Executive summary of the Third Report of the National Cholesterol Education Program. JAMA 2001;285:2486- 2497.

8. Caro F. Jose. Insulin resistance in Obese and Nonobese Man. J Clin Endocrinol Metabol 1991;73:6913-695.

9. Newby D.E., McLeod A.L., Uren N.G. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherosclerosis. Circulation 2001;10:3915:1936-1941 .

10. Ridker P., Rifai N., Rose L. et al. Comparison of С reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:20:1557-1565.

11. Карпов Ю.А., Сорокин Е.В. Первичная профилактика сердечно- сосудистых заболеваний: новые ориентиры. Рус мед журн 2002;19:163:847-850.

12. Juhan-Vague I.,Thompson S.G. Involvement of the Hemostatic System in the Insulin Resistance Syndrome. A Study of 1500 Patients With Angina Pectoris. Arterioscler Thromb 1988;13:12:1865- 1873.

13. Moller S., Stefen H., Weller P. Changes in plasma norepinephrine concentration and thrombocyte alpha2-adrenoreceptor density during long-term antihypertensive therapy with nitrendipine and captopril. J Cardiovasc Pharmacol 1994;24:3:429-433.

14. Моисеева О.М., Беркович О.А., Виллеваде С.В. и др. Динамика функционального состояния клеток крови и эндотелия у больных гипертонической болезнью на фоне терапии эналаприла малеатом. Российский кардиол. журн. 2003;6:44:33-37.